The global sales of the critical care drugs market are projected to grow at a steady CAGR of around 5% to 6% between 2022 and 2032, generating substantial revenues by the end of the forecast period. Growth in the market is attributable to the increasing prevalence of various chronic diseases across the world along with the rising need for better pain management during complex surgeries.
| Report Attribute | Details |
|---|---|
| Critical Care Drugs Market Projected Growth Rate (2022 to 2032) | 5% - 6% CAGR |
Critical care drugs are medicines used in an emergency for treating patients with life-threatening injuries and illnesses. These types of drugs are mostly used in specific care units such as coronary care units and intensive care units.
Numerous critical care drugs such as opioids, sedatives, and benzodiazepines are being increasingly used across trauma centers and hospitals for saving the lives of patients as well as for helping them to recover from serious injuries and illnesses. Apart from these, several life-saving drugs including adrenaline, sodium bicarbonate, calcium gluconate, etc. also fall in the critical care drugs category.
Critical care drugs can also be used for various symptoms or conditions like chest pain, injuries, cardiac arrest, etc. The rising prevalence of life-threatening diseases and accidents is a major factor boosting the sales of critical care drugs.
Similarly, the rapid expansion of the healthcare industry coupled with increasing research and development activities for introducing new critical care drugs will further expand the size of critical care drugs in the future.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The increasing prevalence of critical illnesses across the world, a rise in the number of road accidents, an upsurge in surgeries, and the introduction of novel critical care therapeutics are some of the major factors boosting the sales of critical care drugs.
Critical care drugs have become essential medicines used across intensive care units for treating patients. Consumption of these drugs relieves pain and helps patients to recover at faster speeds.
The rising incidence of road accidents is emerging as a key factor in boosting the growth of the critical care drugs market and the trend is likely to continue in the future. According to the Centers for Disease Control and Prevention (CDC), each year around 1.35 million people are killed on roadways across the world.
Similarly, the increasing number of surgeries performed across the world will continue to fuel the adoption of critical care drugs during the forecast period. Critical care drugs like opioids, morphine, sedatives, and anesthetics are being increasingly used for pain management during and after surgeries.
In addition to this, an increase in the number of end-user verticals such as intensive care units (ICUs), coronary care units (CCUs), operation theaters, and trauma centers is anticipated to create growth prospects within the global critical care drugs market in the forthcoming years.
Although critical care drugs have become essential emergency products, there are various factors that are likely to act as restraints for market growth. Some of these factors are the side effects associated with critical care drugs and the unavailability of various products across some regions.
Principal Consultant
North America was the largest market for critical care drugs in 2022 and is likely to retain its top position during the forecast period. Growth in the market is attributable to the heavy presence of leading pharmaceutical giants, increasing incidence of chronic diseases and accidents, well-established healthcare industry, and easy availability of various critical care drugs.
Demand for critical care drugs is particularly high across the USA due to the rising patient pool and increasing usage of critical care drugs during surgeries. According to the Society of Critical Care Medicine (SCCM), over 5 million patients are admitted annually to USA ICUs for the management of injuries or illness, monitoring support of breathing or circulation; maximization of comfort for dying patients, and stabilization of life-threatening medical problems.
Moreover, increasing investments and efforts of leading market players based in the USA for developing novel critical care drugs with more effectiveness will further expand the size of the critical care drugs market in the future.
According to Future Market Insights, the critical care market in the Asia Pacific is slated to grow at a relatively faster CAGR over the forecast period, owing to the rapidly growing population, increasing healthcare awareness among people, rise in the number of surgeries performed, and expansion of the healthcare industry.
Emerging nations like China and India are experiencing high demand for critical care drugs and the trend is likely to pertain during the forecast period. These drugs are being increasingly used across hospitals and ambulatory and trauma centers for critically ill patients and relieve pain during surgeries. The rise in the number of diseases and surgeries will therefore continue to push the sales of critical care drugs across these nations in the future.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Some of the key participants present in the global critical care drugs market include Pfizer Inc., Abbott, Cadila Pharmaceutica, Neon Laboratories Limited, Triveni chemicals, Haffkine Bio-Pharmaceutical Corporation Ltd., and Cambrex Corporation among others.
These key players are vigorously investing in research and development activities to introduce novel critical care drugs with better efficiency and lower costs. Moreover, they have adopted various organic and inorganic strategies such as partnerships, acquisitions, strengthening of distribution channels, and establishment of new facilities across key attractive regions to expand tehri global footprint.
| Report Attribute | Details |
|---|---|
| Growth Rate | CAGR of 5% - 6% from 2022 to 2032 |
| Base Year for Estimation | 2021 |
| Historical Data | 2015 to 2020 |
| Forecast Period | 2022 to 2032 |
| Quantitative Units | Revenue in USD Million, Volume in Kilotons, and CAGR from 2022 to 2032 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis |
| Segments Covered | Drug Type, End User, Region |
| Regions Covered | North America; Latin America; Western Europe; Eastern Europe; Asia Pacific Excluding Japan; Japan; Middle East and Africa |
| Key Countries Profiled | USA, Canada, Brazil, Argentina, Germany, United Kingdom, France, Spain, Italy, Nordics, BENELUX, Australia & New Zealand, China, India, ASIAN, GCC Countries, South Africa |
| Key Companies Profiled | Pfizer Inc.; Abbott; Cadila Pharmaceutica; Triveni Chemicals; Haffkine Bio-Pharmaceutical Corporation Ltd.; Neon Laboratories Limited; Cambrex Corporation |
| Customization | Available Upon Request |
FMI projects the global sales of critical care drugs market to rise at around 5% to 6% CAGR through 2032.
Asia Pacific is expected to emerge as the most attractive market for the manufacturers of critical care drug manufacturers during the forecast period.
Pfizer Inc., Abbott, Cadila Pharmaceutica, and Triveni chemicals, are some prominent critical care drugs manufacturers
1. Executive Summary | Critical Care Drugs Market 1.1. Global Market Outlook 1.2. Demand-side Trends 1.3. Supply-side Trends 1.4. Technology Roadmap Analysis 1.5. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Background 3.1. Market Dynamics 3.1.1. Drivers 3.1.2. Restraints 3.1.3. Opportunity 3.1.4. Trends 3.2. Scenario Forecast 3.2.1. Demand in Optimistic Scenario 3.2.2. Demand in Likely Scenario 3.2.3. Demand in Conservative Scenario 3.3. Opportunity Map Analysis 3.4. Investment Feasibility Matrix 3.5. Value Chain Analysis 3.5.1. Profit Margin Analysis 3.5.2. Service Providers 3.6. PESTLE and Porter’s Analysis 3.7. Regulatory Landscape 3.7.1. By Key Regions 3.7.2. By Key Countries 3.8. Regional Parent Market Outlook 4. Global Market Analysis 2017 to 2021 and Forecast, 2022 to 2032 4.1. Historical Market Size Value (US$ Million) Analysis, 2017 to 2021 4.2. Current and Future Market Size Value (US$ Million) Projections, 2022 to 2032 4.2.1. Y-o-Y Growth Trend Analysis 4.2.2. Absolute $ Opportunity Analysis 5. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Drug Type 5.1. Introduction / Key Findings 5.2. Historical Market Size Value (US$ Million) Analysis By Drug Type, 2017 to 2021 5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Drug Type, 2022 to 2032 5.3.1. Analgesics 5.3.2. Sedatives/Reversal Agents 5.3.3. Neuromuscular Blocking Agents 5.3.4. Vasoactive and Inotropic Agent 5.3.5. Antihypertensive Drugs 5.3.6. Anticoagulants 5.3.7. Antiarrhythmic Drugs 5.3.8. Adrenergic Agonist Drugs 5.3.9. Anti-infective Drugs 5.3.10. Antibiotic Drugs 5.3.11. Diuretics 5.3.12. ACE Inhibitors 5.3.13. Others 5.4. Y-o-Y Growth Trend Analysis By Drug Type, 2017 to 2021 5.5. Absolute $ Opportunity Analysis By Drug Type, 2022 to 2032 5.6. Deep-dive segmentation will be available in the sample on request 6. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Indication 6.1. Introduction / Key Findings 6.2. Historical Market Size Value (US$ Million) Analysis By Indication, 2017 to 2021 6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Indication, 2022 to 2032 6.3.1. Renal Disorders 6.3.2. Cardiovascular Disorders 6.3.3. Pulmonary Disease 6.3.4. Infectious Disease 6.3.5. Gastrointestinal Disorders 6.3.6. Neurologic Disorders 6.3.7. Hematologic and Oncologic Disorders 6.3.8. Surgery and Trauma 6.4. Y-o-Y Growth Trend Analysis By Indication, 2017 to 2021 6.5. Absolute $ Opportunity Analysis By Indication, 2022 to 2032 6.6. Deep-dive segmentation will be available in the sample on request 7. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By End User 7.1. Introduction / Key Findings 7.2. Historical Market Size Value (US$ Million) Analysis By End User, 2017 to 2021 7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End User, 2022 to 2032 7.3.1. Intensive Care Units (ICU) 7.3.2. Cardiac Care Units (ICU) 7.3.3. Operation Theatres 7.3.4. Trauma Centers 7.4. Y-o-Y Growth Trend Analysis By End User, 2017 to 2021 7.5. Absolute $ Opportunity Analysis By End User, 2022 to 2032 7.6. Deep-dive segmentation will be available in the sample on request 8. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Region 8.1. Introduction 8.2. Historical Market Size Value (US$ Million) Analysis By Region, 2017 to 2021 8.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2022 to 2032 8.3.1. North America 8.3.2. Latin America 8.3.3. Europe 8.3.4. East Asia 8.3.5. South Asia & Pacific 8.3.6. Middle East and Africa 8.4. Market Attractiveness Analysis By Region 9. North America Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country 9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021 9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032 9.2.1. By Country 9.2.1.1. USA 9.2.1.2. Canada 9.2.2. By Drug Type 9.2.3. By Indication 9.2.4. By End User 9.3. Market Attractiveness Analysis 9.3.1. By Country 9.3.2. By Drug Type 9.3.3. By Indication 9.3.4. By End User 9.4. Key Takeaways 10. Latin America Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country 10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021 10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032 10.2.1. By Country 10.2.1.1. Mexico 10.2.1.2. Brazil 10.2.1.3. Rest of Latin America 10.2.2. By Drug Type 10.2.3. By Indication 10.2.4. By End User 10.3. Market Attractiveness Analysis 10.3.1. By Country 10.3.2. By Drug Type 10.3.3. By Indication 10.3.4. By End User 10.4. Key Takeaways 11. Europe Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country 11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021 11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032 11.2.1. By Country 11.2.1.1. Germany 11.2.1.2. Italy 11.2.1.3. France 11.2.1.4. United Kingdom 11.2.1.5. Spain 11.2.1.6. BENELUX 11.2.1.7. Russia 11.2.1.8. Rest of Europe 11.2.2. By Drug Type 11.2.3. By Indication 11.2.4. By End User 11.3. Market Attractiveness Analysis 11.3.1. By Country 11.3.2. By Drug Type 11.3.3. By Indication 11.3.4. By End User 11.4. Key Takeaways 12. East Asia Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country 12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021 12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032 12.2.1. By Country 12.2.1.1. China 12.2.1.2. Japan 12.2.1.3. South Korea 12.2.2. By Drug Type 12.2.3. By Indication 12.2.4. By End User 12.3. Market Attractiveness Analysis 12.3.1. By Country 12.3.2. By Drug Type 12.3.3. By Indication 12.3.4. By End User 12.4. Key Takeaways 13. South Asia & Pacific Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country 13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021 13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032 13.2.1. By Country 13.2.1.1. India 13.2.1.2. ASEAN 13.2.1.3. Australia and New Zealand 13.2.1.4. Rest of South Asia & Pacific 13.2.2. By Drug Type 13.2.3. By Indication 13.2.4. By End User 13.3. Market Attractiveness Analysis 13.3.1. By Country 13.3.2. By Drug Type 13.3.3. By Indication 13.3.4. By End User 13.4. Key Takeaways 14. Middle East and Africa Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country 14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021 14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032 14.2.1. By Country 14.2.1.1. GCC Countries 14.2.1.2. Turkey 14.2.1.3. South Africa 14.2.1.4. Rest of Middle East and Africa 14.2.2. By Drug Type 14.2.3. By Indication 14.2.4. By End User 14.3. Market Attractiveness Analysis 14.3.1. By Country 14.3.2. By Drug Type 14.3.3. By Indication 14.3.4. By End User 14.4. Key Takeaways 15. Key Countries Market Analysis 15.1. USA 15.1.1. Pricing Analysis 15.1.2. Market Share Analysis, 2021 15.1.2.1. By Drug Type 15.1.2.2. By Indication 15.1.2.3. By End User 15.2. Canada 15.2.1. Pricing Analysis 15.2.2. Market Share Analysis, 2021 15.2.2.1. By Drug Type 15.2.2.2. By Indication 15.2.2.3. By End User 15.3. Mexico 15.3.1. Pricing Analysis 15.3.2. Market Share Analysis, 2021 15.3.2.1. By Drug Type 15.3.2.2. By Indication 15.3.2.3. By End User 15.4. Brazil 15.4.1. Pricing Analysis 15.4.2. Market Share Analysis, 2021 15.4.2.1. By Drug Type 15.4.2.2. By Indication 15.4.2.3. By End User 15.5. Germany 15.5.1. Pricing Analysis 15.5.2. Market Share Analysis, 2021 15.5.2.1. By Drug Type 15.5.2.2. By Indication 15.5.2.3. By End User 15.6. Italy 15.6.1. Pricing Analysis 15.6.2. Market Share Analysis, 2021 15.6.2.1. By Drug Type 15.6.2.2. By Indication 15.6.2.3. By End User 15.7. France 15.7.1. Pricing Analysis 15.7.2. Market Share Analysis, 2021 15.7.2.1. By Drug Type 15.7.2.2. By Indication 15.7.2.3. By End User 15.8. United Kingdom 15.8.1. Pricing Analysis 15.8.2. Market Share Analysis, 2021 15.8.2.1. By Drug Type 15.8.2.2. By Indication 15.8.2.3. By End User 15.9. Spain 15.9.1. Pricing Analysis 15.9.2. Market Share Analysis, 2021 15.9.2.1. By Drug Type 15.9.2.2. By Indication 15.9.2.3. By End User 15.10. BENELUX 15.10.1. Pricing Analysis 15.10.2. Market Share Analysis, 2021 15.10.2.1. By Drug Type 15.10.2.2. By Indication 15.10.2.3. By End User 15.11. Russia 15.11.1. Pricing Analysis 15.11.2. Market Share Analysis, 2021 15.11.2.1. By Drug Type 15.11.2.2. By Indication 15.11.2.3. By End User 15.12. China 15.12.1. Pricing Analysis 15.12.2. Market Share Analysis, 2021 15.12.2.1. By Drug Type 15.12.2.2. By Indication 15.12.2.3. By End User 15.13. Japan 15.13.1. Pricing Analysis 15.13.2. Market Share Analysis, 2021 15.13.2.1. By Drug Type 15.13.2.2. By Indication 15.13.2.3. By End User 15.14. South Korea 15.14.1. Pricing Analysis 15.14.2. Market Share Analysis, 2021 15.14.2.1. By Drug Type 15.14.2.2. By Indication 15.14.2.3. By End User 15.15. India 15.15.1. Pricing Analysis 15.15.2. Market Share Analysis, 2021 15.15.2.1. By Drug Type 15.15.2.2. By Indication 15.15.2.3. By End User 15.16. ASIAN 15.16.1. Pricing Analysis 15.16.2. Market Share Analysis, 2021 15.16.2.1. By Drug Type 15.16.2.2. By Indication 15.16.2.3. By End User 15.17. Australia and New Zealand 15.17.1. Pricing Analysis 15.17.2. Market Share Analysis, 2021 15.17.2.1. By Drug Type 15.17.2.2. By Indication 15.17.2.3. By End User 15.18. GCC Countries 15.18.1. Pricing Analysis 15.18.2. Market Share Analysis, 2021 15.18.2.1. By Drug Type 15.18.2.2. By Indication 15.18.2.3. By End User 15.19. Turkey 15.19.1. Pricing Analysis 15.19.2. Market Share Analysis, 2021 15.19.2.1. By Drug Type 15.19.2.2. By Indication 15.19.2.3. By End User 15.20. South Africa 15.20.1. Pricing Analysis 15.20.2. Market Share Analysis, 2021 15.20.2.1. By Drug Type 15.20.2.2. By Indication 15.20.2.3. By End User 16. Market Structure Analysis 16.1. Competition Dashboard 16.2. Competition Benchmarking 16.3. Market Share Analysis of Top Players 16.3.1. By Regional 16.3.2. By Drug Type 16.3.3. By Indication 16.3.4. By End User 17. Competition Analysis 17.1. Competition Deep Dive 17.1.1. Pfizer Inc. 17.1.1.1. Overview 17.1.1.2. Product Portfolio 17.1.1.3. Profitability by Market Segments 17.1.1.4. Sales Footprint 17.1.1.5. Strategy Overview 17.1.1.5.1. Marketing Strategy 17.1.1.5.2. Product Strategy 17.1.1.5.3. Channel Strategy 17.1.2. Sanofi SA 17.1.2.1. Overview 17.1.2.2. Product Portfolio 17.1.2.3. Profitability by Market Segments 17.1.2.4. Sales Footprint 17.1.2.5. Strategy Overview 17.1.2.5.1. Marketing Strategy 17.1.2.5.2. Product Strategy 17.1.2.5.3. Channel Strategy 17.1.3. Johnson & Johnson 17.1.3.1. Overview 17.1.3.2. Product Portfolio 17.1.3.3. Profitability by Market Segments 17.1.3.4. Sales Footprint 17.1.3.5. Strategy Overview 17.1.3.5.1. Marketing Strategy 17.1.3.5.2. Product Strategy 17.1.3.5.3. Channel Strategy 17.1.4. Merck & Co., Inc. 17.1.4.1. Overview 17.1.4.2. Product Portfolio 17.1.4.3. Profitability by Market Segments 17.1.4.4. Sales Footprint 17.1.4.5. Strategy Overview 17.1.4.5.1. Marketing Strategy 17.1.4.5.2. Product Strategy 17.1.4.5.3. Channel Strategy 17.1.5. Mylan N.V. 17.1.5.1. Overview 17.1.5.2. Product Portfolio 17.1.5.3. Profitability by Market Segments 17.1.5.4. Sales Footprint 17.1.5.5. Strategy Overview 17.1.5.5.1. Marketing Strategy 17.1.5.5.2. Product Strategy 17.1.5.5.3. Channel Strategy 17.1.6. GlaxoSmithKline plc. 17.1.6.1. Overview 17.1.6.2. Product Portfolio 17.1.6.3. Profitability by Market Segments 17.1.6.4. Sales Footprint 17.1.6.5. Strategy Overview 17.1.6.5.1. Marketing Strategy 17.1.6.5.2. Product Strategy 17.1.6.5.3. Channel Strategy 17.1.7. Eli Lilly and Company 17.1.7.1. Overview 17.1.7.2. Product Portfolio 17.1.7.3. Profitability by Market Segments 17.1.7.4. Sales Footprint 17.1.7.5. Strategy Overview 17.1.7.5.1. Marketing Strategy 17.1.7.5.2. Product Strategy 17.1.7.5.3. Channel Strategy 17.1.8. Novartis AG 17.1.8.1. Overview 17.1.8.2. Product Portfolio 17.1.8.3. Profitability by Market Segments 17.1.8.4. Sales Footprint 17.1.8.5. Strategy Overview 17.1.8.5.1. Marketing Strategy 17.1.8.5.2. Product Strategy 17.1.8.5.3. Channel Strategy 17.1.9. Allergan Plc. 17.1.9.1. Overview 17.1.9.2. Product Portfolio 17.1.9.3. Profitability by Market Segments 17.1.9.4. Sales Footprint 17.1.9.5. Strategy Overview 17.1.9.5.1. Marketing Strategy 17.1.9.5.2. Product Strategy 17.1.9.5.3. Channel Strategy 17.1.10. AstraZeneca plc. 17.1.10.1. Overview 17.1.10.2. Product Portfolio 17.1.10.3. Profitability by Market Segments 17.1.10.4. Sales Footprint 17.1.10.5. Strategy Overview 17.1.10.5.1. Marketing Strategy 17.1.10.5.2. Product Strategy 17.1.10.5.3. Channel Strategy 17.1.11. Teva Pharmaceutical Industries Ltd. 17.1.11.1. Overview 17.1.11.2. Product Portfolio 17.1.11.3. Profitability by Market Segments 17.1.11.4. Sales Footprint 17.1.11.5. Strategy Overview 17.1.11.5.1. Marketing Strategy 17.1.11.5.2. Product Strategy 17.1.11.5.3. Channel Strategy 17.1.12. Sun Pharmaceutical Industries Limited 17.1.12.1. Overview 17.1.12.2. Product Portfolio 17.1.12.3. Profitability by Market Segments 17.1.12.4. Sales Footprint 17.1.12.5. Strategy Overview 17.1.12.5.1. Marketing Strategy 17.1.12.5.2. Product Strategy 17.1.12.5.3. Channel Strategy 17.1.13. Bristol-Myers Squibb Company 17.1.13.1. Overview 17.1.13.2. Product Portfolio 17.1.13.3. Profitability by Market Segments 17.1.13.4. Sales Footprint 17.1.13.5. Strategy Overview 17.1.13.5.1. Marketing Strategy 17.1.13.5.2. Product Strategy 17.1.13.5.3. Channel Strategy 17.1.14. Bayer AG 17.1.14.1. Overview 17.1.14.2. Product Portfolio 17.1.14.3. Profitability by Market Segments 17.1.14.4. Sales Footprint 17.1.14.5. Strategy Overview 17.1.14.5.1. Marketing Strategy 17.1.14.5.2. Product Strategy 17.1.14.5.3. Channel Strategy 17.1.15. Daiichi Sankyo Company, Limited 17.1.15.1. Overview 17.1.15.2. Product Portfolio 17.1.15.3. Profitability by Market Segments 17.1.15.4. Sales Footprint 17.1.15.5. Strategy Overview 17.1.15.5.1. Marketing Strategy 17.1.15.5.2. Product Strategy 17.1.15.5.3. Channel Strategy 17.1.16. Gilead Sciences, Inc. 17.1.16.1. Overview 17.1.16.2. Product Portfolio 17.1.16.3. Profitability by Market Segments 17.1.16.4. Sales Footprint 17.1.16.5. Strategy Overview 17.1.16.5.1. Marketing Strategy 17.1.16.5.2. Product Strategy 17.1.16.5.3. Channel Strategy 17.1.17. F. Hoffmann-La Roche Ltd 17.1.17.1. Overview 17.1.17.2. Product Portfolio 17.1.17.3. Profitability by Market Segments 17.1.17.4. Sales Footprint 17.1.17.5. Strategy Overview 17.1.17.5.1. Marketing Strategy 17.1.17.5.2. Product Strategy 17.1.17.5.3. Channel Strategy 17.1.18. Boehringer Ingelheim GmbH 17.1.18.1. Overview 17.1.18.2. Product Portfolio 17.1.18.3. Profitability by Market Segments 17.1.18.4. Sales Footprint 17.1.18.5. Strategy Overview 17.1.18.5.1. Marketing Strategy 17.1.18.5.2. Product Strategy 17.1.18.5.3. Channel Strategy 17.1.19. Vertex Pharmaceuticals, Inc. 17.1.19.1. Overview 17.1.19.2. Product Portfolio 17.1.19.3. Profitability by Market Segments 17.1.19.4. Sales Footprint 17.1.19.5. Strategy Overview 17.1.19.5.1. Marketing Strategy 17.1.19.5.2. Product Strategy 17.1.19.5.3. Channel Strategy 17.1.20. Sumitomo Dainippon Pharma Co., Ltd. 17.1.20.1. Overview 17.1.20.2. Product Portfolio 17.1.20.3. Profitability by Market Segments 17.1.20.4. Sales Footprint 17.1.20.5. Strategy Overview 17.1.20.5.1. Marketing Strategy 17.1.20.5.2. Product Strategy 17.1.20.5.3. Channel Strategy 18. Assumptions & Acronyms Used 19. Research Methodology
Healthcare
February 2022
REP-GB-575
May 2024
250 pages
Explore Healthcare Insights
View Reports
Critical Care Drugs Market
